Latest News

Data from multiple KEYNOTE clinical trials support the sustained survival benefits of pembrolizumab in non–small cell lung cancer (NSCLC).

Missteps in prescribing and counseling can escalate into catastrophic harm and significant financial liability.

Recent research reveals rising cancer rates among younger and older adults, linking obesity to increased incidence.

Pharmacist Care Day showcased UPMC Health Plan’s commitment to whole-person care through free health services, pharmacist-led outreach, and strong community collaborations in Pittsburgh.

Christina Barrington, PharmD, champions pharmacists' vital role in enhancing health care access and quality, advocating for their recognition as essential providers.

In Danish athletes, long-term anabolic androgenic steroid use was associated with progressively worsened cardiovascular outcomes.

The FDA approves a simplified single-injection treatment for ulcerative colitis, enhancing patient experience with monthly dosing convenience.

A new low-carbon albuterol inhaler shows therapeutic equivalence to original options, suggesting reduced emissions and improved sustainability for patients with asthma and other respiratory conditions.

Oncologists increasingly embrace cell and gene therapies, yet barriers like cost and perceptions of risk hinder broader adoption.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

Lawmakers weigh cost concerns, clinical outcomes, and regulatory barriers as access to these medications evolves.

Explore the impact of extrapyramidal symptoms on patients, including drug-induced parkinsonism and dystonia, and the importance of early detection and management.

A phase 2 trial suggests a stepwise regimen using liposomal irinotecan followed by oxaliplatin may improve progression-free survival over standard treatment.

The FDA updates sotatercept's label, enhancing treatment options for pulmonary arterial hypertension and reducing severe clinical events.

Pharmacy professionals should make informed decisions regarding their individual career paths.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

Language preference significantly impacts access to continuous glucose monitors for type 2 diabetes, revealing critical disparities in diabetes care.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related hot flashes, offers women a new, effective relief option.

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.